{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-029540","form_type":"8-K","ticker":"ANTX","cik":"0001880438","company_name":"AN2 Therapeutics, Inc.","filed_at":"2026-01-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.663846+00:00","generated_at":"2026-05-16T06:34:09.769669+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"AN2 Therapeutics names Sarah Williams as VP, Controller and PAO; CFO Lucy Day salary reduced from Apr 2026","bullets":["Sarah Williams appointed VP, Controller and Principal Accounting Officer, effective Feb 1, 2026.","Lucy Day remains CFO; base salary reduced to $223,600 from April 1, 2026 (current $335,400 until Mar 31).","Williams receives annual base salary of $310,000 with target annual bonus of 30% of base.","Day's severance eligibility reduced to 50% of plan if terminated after April 1, 2026 (non-CIC)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-029540","json":"https://secwatch.observer/filing/0001193125-26-029540.json","markdown":"https://secwatch.observer/filing/0001193125-26-029540.md","text":"https://secwatch.observer/filing/0001193125-26-029540.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526029540/0001193125-26-029540-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526029540/d84725d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T06:34:09.769669+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}